Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2012-08-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the percentage of patients achieving a
response, defined as the percentage of patients achieving complete response, partial response
and stable disease/ no change upon treatment with the combination therapy according to NCI
response criteria (also established according to IWCLL guidelines) upon treatment with a
combination of bendamustine and alemtuzumab.